PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



(51) International Patent Classification 7: A61K 31/00, 31/425, 31/44	A1	(11) International Publication Number: WO 00/04896 (43) International Publication Date: 3 February 2000 (03.02.00
(21) International Application Number: PCT/	GB99/023	du Chesnay-Beauregard, Boîte postale 58, F-3576 Saint-Grégoire (FR).
(22) International Filing Date: 21 July 199	99 (21.07.9	(74) Agent: RUTTER, Keith; SmithKline Beecham, Corporat Intellectual Property, Two New Horizons Court, Brentford Middlesex TW8 9EP (GB).
(30) Priority Data: 9815871.0 21 July 1998 (21.07.98)		B
9815872.8 21 July 1998 (21.07.98) 9905387.8 9 March 1999 (09.03.99) (71) Applicants (for all designated States except US) LINE BEECHAM P.L.C. [GB/GB]; New Hor) C	(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BC BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GE GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KC KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, ME MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, S
Brentford, Middlesex TW8 9EP (GB). SN BEECHAM LABORATOIRES PHARMAC [FR/FR]; 6, esplanade Charles de Gaulle, F-92' Cedex (FR).	MITHKLIN CEUTIQUI	SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SL UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MI RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DE ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAI
(72) Inventors; and (75) Inventors/Applicants (for US only): BRIL, Anto Alain [FR/FR]; SmithKline Beecham Pharmaceutiques, Unité de Recherche, Ru	Laboratois	es
nay-Beauregard, Boîte postale 58, F-35762 Sa (FR). BUCKINGHAM, Robin, Edwin [GB/G line Beecham Pharmaceuticals, New Frontiers South, Third Avenue, Harlow, Essex CM19 KHANDOUDI, Nassirah [FR/FR]; SmithKli Laboratoires Pharmaceutiques, Unité de Rec	aint-Grégo B]; Smith Science Pa 5AW (Gl ine Beecha	With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt amendments.
(54) Title: USE OF GLUCOSE UPTAKE ENHANCE	ER FOR R	EDUCING APOPTOSIS
(57) Abstract		
hate calls and othelial calls and neuronal cells in the	human or	ated cells selected from the list consisting of cardiac myocytes, pancreat non-human mammal, which method comprises administration, including uptake enhancer to a human or non-human mammal in need thereo